Personalizing medicine with clinical pharmacogenetics

Area of Science:

• Pharmacogenetics
• Clinical Genetics
• Molecular Diagnostics

Background:

• Clinical genetic testing has expanded significantly, driven by advances in molecular technologies and identification of disease-causing mutations.
• Pharmacogenetics, established decades ago, is now emerging in clinical practice to personalize drug therapy, influenced by regulatory updates.
• Despite known associations with adverse drug reactions, clinical pharmacogenetic testing adoption by physicians remains limited.

Purpose of the Study:

• To review the current landscape of clinical pharmacogenetic testing.
• To identify opportunities and challenges associated with its implementation in healthcare.
• To understand the reasons behind the slow physician uptake of pharmacogenetic testing.

Main Methods:

• This is a review article, synthesizing existing literature and data on clinical pharmacogenetics.
• The review discusses the evolution of genetic testing and its application in pharmacotherapy.
• It examines barriers to the clinical implementation of pharmacogenetic testing.

Main Results:

• Physician uptake of clinical pharmacogenetic testing is slow, despite its potential to guide pharmacotherapy.
• Lower positive predictive values in certain indications compared to Mendelian disease testing contribute to underutilization.
• Key barriers include issues with clinical utility, professional education, regulatory hurdles, and reimbursement.

Conclusions:

• Implementing clinical pharmacogenetic testing presents both opportunities and significant challenges.
• Addressing barriers related to predictive value, clinical utility, education, and regulation is crucial for broader adoption.
• Further development and evidence are needed to facilitate the integration of pharmacogenetics into routine clinical practice.